Liminatus Pharma, Inc. Class A Common Stock (LIMN)

Liminatus Pharma, Inc. Class A Common Stock (LIMN) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $5M; returns 1 day -5.5%, 1 week -3.3%, 1 year -95.1%.

Liminatus Pharma, Inc. (LIMN) is a clinical-stage immuno-oncology company focused on developing novel cancer therapies. The company's lead candidate is IBA101, a humanized anti-CD47 monoclonal antibody designed to block CD47-SIRPα interactions and restore anti-tumor function of innate immune cells.

Groups LIMN belongs to

• Healthcare
• Recent Reverse Splits
• Biotechnology
• Clinical Stage Biotech
• Oncology
• Immunotherapy
• Monoclonal Antibodies
• Cancer Therapeutics
• Clinical Stage
• Life Sciences
• Biopharmaceutical

LIMN financial model: income statement, cash flow and balance sheet